A phase III Randomized, placebo-controlled, outpatient registrational trial for antiviral candidate, ProLectin-M, targeting standard-risk patients with mild-to-moderate COVID-19 and other viral infections from Influenza, RSV and other viruses
Latest Information Update: 16 Mar 2026
At a glance
- Drugs Galactomannan (Primary)
- Indications COVID 2019 infections; Influenza virus infections; Respiratory syncytial virus infections
- Focus Registrational; Therapeutic Use
- Sponsors BioXyTran
Most Recent Events
- 16 Mar 2026 New trial record